| Company Name | Pfizer Ltd. Taiwan |
|---|---|
| Protocol Number | B7461039 |
| Title of Study | LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES |
| Primary Objective | To monitor the safety and tolerability of study intervention(s) |
| Number of Sites | 1 |
| Period of Study | From：01-Apr-2022 to：01-Apr-2027 |
| Number of Patients | 4人 |
| IRB Approval Date | 25-Mar-2022 |
| Publication Plan / Date | 28-Dec-2027 |
